Latest Communications

18 January 2012
APR Applied Pharma Research s.a. (“APR”), Labtec GmbH (“Labtec”) and Norgine BV (“Norgine”) announce the signature of an exclusive licensing agreement under which Norgine will market and distribute Setofilm™ Ondansetron Oral Dispersible Film (“ODF”), in Europe and selected non-European countries.

12 July 2011
MonoSol Rx Announces Availability of Zuplenz® Oral Soluble Film for Licensing to New Commercialization Partners

13 June 2011
APR Applied Pharma Research s.a. and Labtec GmbH announce Ondansetron Oral Dispersible Film (“ODF”) is now available for licensing in Europe and selected non European countries, after having received marketing authorization in most countries of Europe.


oral

ORAL NUTRACEUTICALS

Project Design Planning



REGULATORY STRATEGY

The first step of the project Design Planning is the evaluation of the best Regulatory Strategy according to customer requirements. APR is able to plan and manage Scientific Advice Meetings with Health Authorities in either EU and US in order get guidance or validate regulatory and development strategies.



SELECTION OF THE BEST DELIVERY SYSTEM

Where the nutraceutical components is/are already defined, APR can exploit the chemical / physical / technological characteristics of the ingredients to determine the valid galenic approach and the best oral unit and dosage form.



INVESTMENT PLAN

This is the last Step of the project Design Planning where APR is able to provide a complete Development Plan including activities, time and costs.


Search results